SCHEMBL4863822

SCHEMBL4863822

Cc1ccc2c(c1)CCCCN2S(=O)(=O)c1ccccc1C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
TP53 P04637 4/20 0.53
MAPT P10636 3/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ATM Q13315 1/20 0.52
CRHBP P24387 2/20 0.51
CRHR2 Q13324 2/20 0.51
MAPK1 P28482 1/20 0.46
TNF P01375 1/20 0.46
NOD2 Q9HC29 1/20 0.46
NOD1 Q9Y239 1/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
NR1H3 Q13133 1/20 0.46
TSHR P16473 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4869072 0.87 CRHBP (0.62) L3MBTL1MEN1KMT2AATMCRHBP
SCHEMBL4871858 0.80 L3MBTL1 (0.45) L3MBTL1TP53MAPTMEN1KMT2A
SCHEMBL2696317 0.76 MEN1 (0.65) L3MBTL1MEN1KMT2ACRHBPCRHR2
SCHEMBL4863832 0.76 RORC (0.59) L3MBTL1TP53MAPTMEN1KMT2A
SCHEMBL10879279 0.75 GAA (0.50) MEN1KMT2ACRHBPCRHR2TSHR
SCHEMBL10066942 0.75 TP53 (0.57) L3MBTL1TP53MAPTMEN1KMT2A
SCHEMBL6369637 0.74 MEN1 (0.43) L3MBTL1MAPTMEN1KMT2AATM
SCHEMBL14601689 0.73 TP53 (0.66) TP53MAPTMEN1KMT2AATM
SCHEMBL31011828 0.73 KMT2A (0.67) L3MBTL1TP53MAPTMEN1KMT2A
SCHEMBL4865019 0.71 KMT2A (0.51) L3MBTL1MAPTMEN1KMT2ACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 L3MBTL1 4626/4885TP53 4170/4885MAPT 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.